CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.22B, above the global median of $1.15B
- FinancialsAltman Z-Score 2.59: grey zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.22BUSDvs all stocks (USD)
Trailing P/E
95.30xvs Medical Devices peers
Revenue (TTM)
458.69MUSDvs all stocks (USD)
Profit Margin
2.55%vs Medical Devices peers
Beta
1.25xvs all stocks
52-Week Change
-18.21%vs all stocks
Market Capitalization
1.22BUSDvs all stocks (USD)
Enterprise Value
1.45BUSDvs all stocks (USD)
Trailing P/E
95.30xvs Medical Devices peers
Forward P/E
35.74xvs Medical Devices peers
PEG Ratio
-0.2382xvs Medical Devices peers
Price to Sales (TTM)
2.72xvs Medical Devices peers
Price to Book (MRQ)
2.77xvs Medical Devices peers
Enterprise to Revenue
3.16xvs Medical Devices peers
Enterprise to EBITDA
23.64xvs Medical Devices peers
Gross Margin
64.85%vs Medical Devices peers
Profit Margin
2.55%vs Medical Devices peers
Operating Margin
5.18%vs Medical Devices peers
Return on Assets (TTM)
2.84%vs Medical Devices peers
Return on Equity (TTM)
3.14%vs Medical Devices peers
Revenue (TTM)
458.69MUSDvs all stocks (USD)
Revenue per Share (TTM)
9.80USDUpdated Jul 18, 2026Quarterly Revenue Growth
17.50%vs Medical Devices peers
Gross Profit (TTM)
296.10MUSDvs all stocks (USD)
EBITDA (TTM)
60.72MUSDvs all stocks (USD)
Net Income (TTM)
11.68MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
17.54%vs Medical Devices peers
Operating Cash Flow (TTM)
57.99MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-7.29MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Medical Devices peers
Revenue
441.33MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
157.10MUSDFY2025 · Dec 31, 2025Gross Profit
284.23MUSDFY2025 · Dec 31, 2025Operating Income
26.75MUSDvs all stocks (USD)
Pre-tax Income
14.78MUSDFY2025 · Dec 31, 2025Income Tax Expense
5.01MUSDFY2025 · Dec 31, 2025Net Income
9.77MUSDFY2025 · Dec 31, 2025EBIT
41.36MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
59.48MUSDFY2025 · Dec 31, 2025Research & Development
30.99MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
226.49MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
763.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
26.58MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
9.77MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
11.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
41.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
64.91MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
9.77MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
22.46MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
37.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
24.39MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.83MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-7.27MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.18MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-15.28MUSDFY2025 · Dec 31, 2025Other Investing Activity
-3.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.00MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-2.46MUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-2.25MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
668.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-4.04MUSDFY2025 · Dec 31, 2025Shares Outstanding
48.50MSharesUpdated Jul 18, 2026Float Shares
45.97MSharesUpdated Jul 18, 2026Shares Short
2.18MSharesUpdated Jul 18, 2026Short Ratio
2.33daysvs all stocks
Short % of Shares Outstanding
5.40%vs all stocks
% Held by Insiders
4.49%vs all stocks
% Held by Institutions
92.57%vs all stocks
Total Cash (MRQ)
55.76MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.15USDUpdated Jul 18, 2026Total Debt (MRQ)
258.16MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.5731xvs Medical Devices peers
Current Ratio (MRQ)
3.86xvs Medical Devices peers
Book Value per Share (MRQ)
9.29USDUpdated Jul 18, 2026Total Assets
884.80MUSDvs all stocks (USD)
Total Current Assets
358.08MUSDFY2025 · Dec 31, 2025Total Liabilities
436.56MUSDFY2025 · Dec 31, 2025Total Non-current Assets
526.71MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
335.01MUSDFY2025 · Dec 31, 2025Total Current Liabilities
101.56MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
64.91MUSDFY2025 · Dec 31, 2025Accounts Receivable
89.76MUSDFY2025 · Dec 31, 2025Inventory
92.43MUSDFY2025 · Dec 31, 2025Accounts Payable
16.04MUSDFY2025 · Dec 31, 2025Short-term Debt
5.38MUSDFY2025 · Dec 31, 2025Other Current Liabilities
25.47MUSDFY2025 · Dec 31, 2025Long-term Debt
252.24MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
49.00MUSDFY2025 · Dec 31, 2025Common Stock (Book)
493.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-51.50MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
448.23MUSDvs all stocks (USD)
Treasury Stock
14.65MUSDFY2025 · Dec 31, 202552-Week Low
19.16USDUpdated Jul 18, 202652-Week High
48.25USDUpdated Jul 18, 202652-Week Change
-18.21%vs all stocks
Beta
1.25xvs all stocks
50-Day MA
23.23USDUpdated Jul 18, 2026200-Day MA
36.70USDUpdated Jul 18, 2026Avg 10-Day Volume
533.03KSharesUpdated Jul 18, 2026Avg 30-Day Volume
812.60KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
0.2700USDUpdated Jul 18, 2026Other Income / Expense
13.85MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
High OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration
Cash covers reported profit and gross profit is up, with margins high and growth slowing.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.65Profit Margin: 0.03
Financial Health
Altman Z-Score 2.59: grey zoneSignificant
Altman Z-Score: 2.59
High earnings qualityNotable
Earnings Quality Score: 0.65
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.22B, above the global median of $1.15BNotable
Market cap (USD): 1,216,496,302Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Carsgen Therapeutics Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Wandong Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kissei Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Viyash Scientific Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sequent Scientific Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Yizhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Easton Bio Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Lukang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xianju Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Planet Fitness Inc.
1 interpretationHigh OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration
Wingstop Inc.
2 interpretationsRevenue Growing With Receivables GrowingHigh OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration
Verra Mobility Corporation
2 interpretationsRevenue Growing With Receivables GrowingHigh OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration